Katsumi Itoh

This inventor holds 21 USPTO granted patents, primarily in Azole Compounds. Top assignees: Takeda Chemical Industries, Inc., Takeda Chemical Industries, Co., Ltd.. Active years: 1978-2002.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Katsumi Itoh. Retrieved from https://idiyas.com/inventor/katsumi-itoh

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21

% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 6

Forward Citations = 142(Granted Patents)

Location History:

Takatsuki, JA (1978)
Takatsuki, JP (1979 - 1980)
Toyonaka, JP (1991)
Toyono, JP (1993 - 1995)
Toyono-cho, JP (1996)
Toyono-gun, JP (1996 - 1998)
Osaka, JP (1989 - 2002)

Company Filing History:

20 out of 1,858

Takeda Chemical Industries, Inc.

patents

1 out of 1

Takeda Chemical Industries, Co., Ltd.

patent

Years Active: 1978-2002

Loading Chart...

Areas of Expertise:

Azole Compounds

Triazole Derivatives

Antifungal Agents

Optically Active Compounds

Piperazine Derivatives

Dihydronaphthalene

Cerebral Function Agents

Fungicidal Compositions

Therapeutic Applications

Chemical Production

Imidazole Compounds

Tetrazole Compounds

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6495604 - Cycloalkene derivatives, process for producing the same, and use (2002-12-17),

2. 6407129 - Azole compounds, their production and their use (2002-06-18),

3. 6362206 - Azole compounds, their production and use (2002-03-26),

4. 6034248 - Azole compounds, their production and use (2000-03-07),

5. 5792780 - Azole compounds, their production and use (1998-08-11),

6. 5677464 - Production of optically active triazole compounds and their intermediates (1997-10-14),

7. 5545652 - Triazole and imidazole compounds and their use as antifungal therapeutic (1996-08-13),

8. 5495024 - Optically active azole compounds and their production (1996-02-27),

9. 5466820 - Production of Di or tri-azolyl substituted 5-keto azole compounds (1995-11-14),

10. 5405861 - Triazole compounds and antifungal compositions thereof (1995-04-11),

11. 5389663 - 1-(1h-1,2,4-triazole-yl)-2-propanol compounds (1995-02-14),

12. 5387599 - Triazoles, their production and use (1995-02-07),

13. 5371101 - Azole compounds, their production and use (1994-12-06),

14. 5371100 - Optically active tetrazole compounds, and fungicidal compositions thereof (1994-12-06),

15. 5177094 - Triazole compounds having antifungal properties (1993-01-05),

Title: Katsumi Itoh: Innovator and Pioneer in Pharmaceutical Chemistry

Introduction: Katsumi Itoh, based in Osaka, Japan, is an esteemed inventor recognized for his contributions to pharmaceutical chemistry. With a remarkable portfolio of 21 patents, Itoh has significantly impacted the development of novel compounds used in medical applications.

Latest Patents: Among his latest groundbreaking patents are innovative compounds such as cycloalkene derivatives, which detail processes for their production and applications. Notably, Itoh has developed azole compounds that demonstrate improved solubility in water, making them suitable for injection. His quaternized nitrogen-containing imidazol-1-yl and 1,2,4-triazol-1-yl compounds can be converted in vivo to antifungal agents, showcasing their potential in treating or preventing diseases effectively.

Career Highlights: Throughout his career, Katsumi Itoh has been associated with renowned organizations, including Takeda Chemical Industries, Inc. and Takeda Chemical Industries, Co., Ltd. His expertise and innovative spirit have played a vital role in advancing pharmaceutical technologies and compounds.

Collaborations: Itoh has worked alongside notable colleagues such as Kenji Okonogi and Akihiro Tasaka. Together, they have contributed to developing innovative solutions in the field of pharmaceutical sciences.

Conclusion: Katsumi Itoh remains a key figure in the domain of pharmaceutical inventions, with a progressive body of work that includes numerous patents. His innovations have the potential to improve treatment options and enhance patient outcomes in the medical field.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]